Elu­ci­da On­col­o­gy nabs more funds for its take on AD­Cs, sees po­ten­tial in ra­dio­ther­a­py part­ner­ship

Elu­ci­da On­col­o­gy has raised an­oth­er ap­prox­i­mate­ly $30 mil­lion to bring its ver­sion of an­ti­body-drug con­ju­gates to more pa­tients in the clin­i­cal set­ting, the com­pa­ny told End­points News.

The CDC has a dif­fer­ent mean­ing over at the New Jer­sey biotech, which is de­vel­op­ing what it calls “C’Dot-Drug-Con­ju­gates.” The goal is to bet­ter at­tack can­cer­ous tis­sue with small­er-sized nanopar­ti­cles, more po­ten­cy and less ad­verse im­pact on pa­tients’ health. Elu­ci­da’s take on the class of AD­Cs, which have bal­looned in R&D pop­u­lar­i­ty and sur­passed the dozen mile­stone in terms of reg­u­la­to­ry ap­provals, start­ed in the labs of Cor­nell and has gone through fur­ther de­vel­op­ment at Memo­r­i­al Sloan Ket­ter­ing. The com­pa­ny came to­geth­er a lit­tle un­der a decade ago, per SEC fil­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER